JETO HomeIssue Contents

Cost analysis of intra-arterial versus intravenous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme
Jan-Karl Burkhardt, Benjamin J. Shin, Cody D. Schlaff, Howard Riina and John A. Boockvar

Intra-arterial bevacizumab (IA BV) has been recently identified to be safe in the treatment of recurrent GBM. In this study, we sought to perform a cost analysis of IA BV versus IV BV especially also taking account of patient progression free survival (PFS) and overall survival (OS). We show that IA BV is significantly more cost effective than conventional IV therapy.

Keywords: Cost-Effectiveness, Intra-arterial Bevacizumab, Recurrent Glioblastoma Multiforme

Full Text (IP)